Premium
Interferon in the treatment of cutaneous T‐cell lymphoma
Author(s) -
Olsen Elise A.
Publication year - 2003
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1396-0296.2003.01643.x
Subject(s) - medicine , cutaneous t cell lymphoma , interferon , lymphoma , pharmacokinetics , in vivo , mycosis fungoides , alpha interferon , interferon alfa , oncology , side effect (computer science) , pharmacology , dermatology , immunology , microbiology and biotechnology , computer science , biology , programming language
Interferons are polypeptides with a broad range of in vivo effects that have shown efficacy in cutaneous T‐cell lymphoma (CTCL). Particularly useful is alfa interferon (IFN) which, as a single agent, has shown partial remission rates of > 50% and complete responses of > 20%. Side‐effects are predictable, generally well tolerated and dose‐related. The efficacy of IFN has increased with combination therapy without any significant increase in attendant side‐effects. An update on the specifics of the different IFN subtypes, their inherent biologic activity, pharmacokinetics, efficacy and safety in CTCL is presented in this paper.